Abvc biopharma adhd phase ii part 2 clinical study first subject treated

Fremont, ca, may 10, 2022 (globe newswire) -- via newmediawire – abvc biopharma, inc. (nasdaq: abvc), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced that the first subject began treatment at the cheng hsin general hospital in the phase ii part 2 clinical study of the company's adhd medicine (abv-1505).  the study, entitled “a phase ii tolerability and efficacy study of pdc-1421 treatment in adult patients with attention-deficit hyperactivity disorder (adhd), part ii,” is a randomized, double-blind, placebo-controlled study involving a total of approximately 100 patients in the united states and taiwan. this is a continuation of the phase ii part 1 study of abv-1505, which was completed successfully at the university of california, san francisco and accepted by the u.s. food & drug administration in october 2020.
ABVC Ratings Summary
ABVC Quant Ranking